Announcements

Opyl response to ASX Questions

Opyl Appendix 3Y Change of Director’s Interest – D Rasheed

Opyl Board and Management Change

Notice of 2020 Annual General Meeting

Opyl receives $249k R&D tax refund

Opyl 2020 Annual General Meeting Results

Opyl – Expiry of Unlisted Options

Opyl Appendix 4C – Quarter (Q1) ending 31 December 2020

Opyl’s artificial intelligence will change clinical trials forever

Opyl Implements Unmarketable Parcel Share Sale Facility

Opyl H1 FY 2021